Gentrafix™
Revolutionising the treatment of genetic diseases by intercellular transmission of DNA
Bitrobius Genetics is developing Gentrafix™: the only technology capable of delivering DNA to every cell where it is needed. A Gentrafix™ plasmid will replicate following delivery, then spread to adjacent cells, carrying the correct copy of a gene that is mutated in those cells and thereby curing the genetic disease. We are expanding its application into mitochondrial gene therapy.
Our Investors
There are no permanent cures for most genetic diseases...
…and the few gene therapies on the market represent the most expensive medicines in history.
Current gene therapy vectors, which are mostly modified viruses, are unable to carry the large genes needed to treat most diseases and can only reach a few percent of the afflicted cells.
There are no gene therapies to treat diseases caused by mutations of mitochondrial genes.
Gentrafix™ represents a paradigm shift in the treatment of genetic diseases
It enables cost-effective manufacture with the potential to deliver even the largest human gene to all the cells where it is needed.
The Gentrafix™ technology is based on DNA molecules called plasmids which are uniquely able to replicate within human cells and then travel to adjacent cells via a translocation mechanism, thus spreading throughout the affected cells.
We are developing cures for a range of genetic diseases
The gene therapies that we plan to develop are for diseases for which there are no effective treatments, or the therapies that do exist are very expensive or of limited scope or duration.
Meet the team
Our highly experienced team have many years of academic and industrial experience at the cutting edge of molecular genetics and biotechnology research and development.